What the company or idea is
China Biologic Products is a plasma-derived biopharmaceutical manufacturer, operating primarily through its majority-owned subsidiary Shandong Taibang.
How it actually makes money
It sells plasma-derived therapeutics—human albumin and immunoglobulin—to Chinese hospitals and healthcare facilities.
What works
Its sole provincial approval gives it de facto market insulation in Shandong. Its focus on two established plasma products—albumin and immunoglobulin—matches stable clinical demand in Chinese hospitals.
What does not
It does not operate outside China’s hospital distribution system. It does not develop novel biologics or gene therapies. It does not disclose manufacturing costs, margins, or plasma collection volumes.
What to take from it
Its value lies in its monopoly position within Shandong Province—not in innovation, but in regulatory exclusivity and control over plasma sourcing and hospital sales channels.
Is it worth your time
Yes, if you are assessing how provincial regulatory approval, vertical integration in plasma supply, and private equity consolidation shape biopharma access in China.
